AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
Dr. Gregory Bell named Exceptional Expert in Power Players report on International Arbitration
Financier Worldwide Magazine featured CRA’s Dr. Gregory Bell as an Exceptional Expert in the Power Players report on International Arbitration.